🔎 Trials Near Me

Beranda › Obesitas › Arizona › Phoenix

Uji klinis Obesitas di Phoenix, AZ

22 studi untuk Obesitas mencari peserta di lokasi sekitar Phoenix (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Early Tracking of Childhood Health Determinants (ETCHED) Study

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • NIDDK, Phoenix, Phoenix
1 Day – 99 Years · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03481829

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Menerima pesertaFase 3
  • RIO Clinical Trials - Phoenix, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Menerima pesertaFase 3
  • Research Site, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Menerima pesertaFase 3
  • Synexus Clinical Research US, Inc., Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
Usia 45 hingga 99 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Menerima pesertaFase 3
  • Elite Clinical Studies, LLC, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07353931

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Menerima pesertaSukarelawan sehat diterima
  • NIDDK, Phoenix, Phoenix
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06223555

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Menerima pesertaFase 3
  • AURORA-1 Clinical Site, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Menerima pesertaFase 3
  • AURORA-2 Clinical Site, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Menerima pesertaFase 3
  • HonorHealth, Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Menerima pesertaFase 2
  • Helios Clinical Research - Phoenix, Phoenix
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Menerima pesertaFase 3Sukarelawan sehat diterima
  • ACCOMPLISH-2 Research Site, Phoenix
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07654374

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Menerima pesertaFase 2
  • Synexus Clinical Research US, Inc., Phoenix
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07215559

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Menerima pesertaFase 3
  • Kailera Clinical Site, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284901

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Menerima pesertaFase 3
  • Kailera Clinical Site, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07284979

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Menerima pesertaSukarelawan sehat diterima
  • NIDDK, Phoenix, Phoenix
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05545306

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

Menerima pesertaStudi observasional
  • Exponent Phoenix, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07776678

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Menerima pesertaFase 3
  • Honor Health, Phoenix
  • Arizona Research Center, Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Menerima pesertaFase 3
  • ACCOMPLISH-1 Research Site, Phoenix
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07654361

Fibrosis Lessens After Metabolic Surgery

Menerima pesertaFase 4Sukarelawan sehat diterima
  • Banner Health Center, Phoenix
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06374875

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Menerima pesertaFase 3
  • Arizona Research Center, Inc., Phoenix
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07481630

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Menerima pesertaFase 3
  • The University of Arizona College of Medicine- Phoenix, Phoenix
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Nov 2025 · NCT06499857

Uji klinis Obesitas di kota lain

Studi lain di Phoenix

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.